Findings

What do systematic reviews say?

117 questions · 120 findings · 21 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 29 · 24.2%GRADE not reported 5 · 4.2%Very low 44 · 36.7%Low 30 · 25%Moderate 7 · 5.8%High 5 · 4.2%

IVIg vs placebo

Survival time · NSTI

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Low

IVIg vs placebo

Assessment of long‐term morbidity · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Moxifloxacin vs amoxicillin‐clavulanate

SAEs · NSTI

It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 0.63 [0.3, 1.31]
1 study · 54 participants
Very low

Moxifloxacin vs amoxicillin‐clavulanate

Survival time · NSTI

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Moxifloxacin vs amoxicillin‐clavulanate

Assessment of long‐term morbidity · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

AB103 vs placebo

All‐cause mortality · NSTI

It is very uncertain whether AB103 changes mortality compared with placebo (very low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 0.34 [0.05, 2.16]
1 study · 43 participants
Very low

AB103 vs placebo

SAEs · NSTI

It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 1.49 [0.52, 4.27]
1 study · 43 participants
Very low

AB103 vs placebo

Survival time · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

AB103 vs placebo

Assessment of long‐term morbidity · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

All‐cause mortality · NSTI

Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 1.17 [0.42, 3.23]
1 study · 100 participants
Low

Nivolumab vs no other intervention

OS · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 260 participants
Very low

Nivolumab vs no other intervention

QoL · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Nivolumab vs no other intervention

PFS · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

Response rate · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

Treatment‐related mortality · adults with Hodgkin's lymphoma

The review found no eligible studies for this question.

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nivolumab vs no other intervention

Grades 3 and 4 adverse events · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

SAEs · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 243 participants
Very low